Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States-Reference-Cited by-同舟云学术

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States

Published:2024-07-05 Issue: Volume: Page:1-10
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Toreli Ana Carolina Mourão¹,Miranda-Galvis Marisol²^ORCID,Sharara Muhannad²,Addas-Carvalho Marcelo¹^ORCID,Miranda Eliana¹^ORCID,Fechio Leonardo¹,Silva Santos Duarte Adriana¹,Basso Audrey¹^ORCID,Duarte Gislaine¹,Souza Medina Samuel¹,Pericole Fernando¹,Benites Bruno¹^ORCID,Jones Kimya³,Singh Harmanpreet³,Farmaha Jaspreet³,Vashisht Ashutosh³,Kolhe Ravindra³,Mondal Ashis K.³,Saad Sara Teresinha Olalla¹^ORCID,de Souza Carmino Antonio¹^ORCID,Cortes Jorge E.²^ORCID,Pagnano Katia¹^ORCID

Affiliation:

1. Centro de Hematologia e Hemoterapia (Hemocentro-UNICAMP), Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil

2. Georgia Cancer Center, Augusta University, Augusta, GA, USA

3. Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPQ

CNPQ/MCTIC

Augusta University to Dr. Kolhe

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2367057

Reference27 articles.

1. COVID-19 in patients with hematologic malignancy

2. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

3. Immunogenicity of COVID-19 vaccines in patients with hematological malignancy: a systematic review and meta-analysis

4. Ethno‐demographic disparities in humoral responses to the COVID‐19 vaccine among healthcare workers

5. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis